ARCHIVES

Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.

This article is from The Cancer Letter archive.

Vol. 30 No. 18 | April 30, 2004

Download PDF Visit The Full Archive

Related Articles

NCI Receives 165 SBIR Grant Applications; Combines With Solid Contracts, No More Fiascos Are Expected

June 14, 1985

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

November 7, 2003

NCI Programs: Report Calls for Expansion of Colorectal Cancer Research

April 28, 2000

NCCN Launches Outcomes Improvement Program

August 12, 2011

Cancer Deaths Level Off For First Time, Klausner Tells House Appropriators.

February 18, 2000

Oncology Management: US Oncology To Conduct Up To 5 Studies Of PG-TXL In Colorectal, Lung Cancers

June 1, 2001